Guía de Práctica Clínica sobre Trastorno Bipolar - GuíaSalud

276. Tohen M, Calabrese J, Vieta E, Bowden C, Gonzalez-Pinto A, Lin D, Xu W y Corya S.
Effect of comorbid anxiety on treatment response in bipolar depression. Journal of
affective disorders, 2007; 104 (1-3): 137-146.
277. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M y Patelis-Siotis I. Doubleblind
comparison of addition of a second mood stabilizer versus an antidepressant to an
initial mood stabilizer for treatment of patients with bipolar depression. American Journal
of Psychiatry, 2000; 157: 124-126.
278. Azorin JM y Kaladjian A. An update on the treatment of bipolar depression. Expert
OpinPharmacother, 2009.
279. Licht RW, Gijsman H, Nolen WA y Angst J. Are antidepressants safe in the treatment of
bipolar depression? A critical evaluation of their potential risk to induce switch into
mania or cycle acceleration. Acta Psychiatrica Scandinavica, 2008; 118 (5): 337-346.
280. Van Lieshout RJ y MacQueen GM. Efficacy and acceptability of mood stabilisers in the
treatment of acute bipolar depression: systematic review. Br J Psychiatry, 2010; 196:
266-273.
281. Frangou S, Lewis M y McCrone P. Efficacy of ethyl-ecosapentaenic acid in bipolar
depression: randomised double-blind placebo-controlled study,. British Journal of
Psychiatry, 2006; 188: 46-50.
282. Frangou S, Lewis M, Wollard J y Simmons A. Preliminary in vivo evidence of increased
N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar
disorder. Journal of psychopharmacology (Oxford, England), 2007; 21 (4): 435-439.
283. Keck PE, Jr., Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, Marcus
RN y Sanchez R. A randomized, double-blind, placebo-controlled 26-week trial of
aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry, 2006; 67
(4): 626-637.
284. Muskiet FA y Kemperman RF. Folate and long-chain polyunsaturated fatty acids in
psychiatric disease. JNutrBiochem,, 2006.
285. Ross BM, Seguin J y Sieswerda LE. Omega-3 fatty acids as treatments for mental illness:
which disorder and which fatty acid? Lipids in health and disease, 2007; 6: 21-40.
286. Keck PE, Mintz J, McElroy SL, Freeman MP, Suppes T, Frye MA, Altshuler LL, Kupka
R, Nolen WA, Leverich GS, Denicoff KD, Grunze H, Duan N y Post RM. Double-blind,
randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of
bipolar depression and rapid cycling bipolar disorder. Biological psychiatry, 2006; 60 (9):
1020-1022.
287. Gallagher P, Malik N, Newham J, Young AH, Ferrier IN y Mackin P. Antiglucocorticoid
treatments for mood disorders. Cochrane database of systematic reviews (Online), 2008;
1 (1): CD005168.
288. Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE, Walden J, Leverich GS, Altshuler
LL, Nakelsky S, Hwang S, Mintz J y Post RM. A placebo-controlled evaluation of
adjunctive modafinil in the treatment of bipolar depression. The American Journal of
Psychiatry, 2007; 164 (8): 1242-1249.
289. Calabrese J, Ketter T, Youakim J, Tiller J, Yang R y Frye M. Adjunctive armodafinil for
major depressive episodes associated with bipolar I disorder: a randomized, multicenter,
double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry, 2010; 71
(10): 1363-1370.
290. Furey ML y Drevets WC. Antidepressant efficacy of the antimuscarinic drug
scopolamine: a randomized, placebo-controlled clinical trial. Archives of General
Psychiatry, 2006; 63 (10): 1121-1129.
291. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL y
Soares JC. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of
bipolar disorder: a double-blind, randomized, placebo-controlled study. Human
psychopharmacology, 2008; 23 (2): 87-94.
292. Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ,
Miyahara S, Bauer MS, Thase ME, Wisniewski SR y Sachs GS. Treatment-resistant
416 SANIDAD